TITAN BIOTECH
|
TITAN BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 30.06 | 26.24 | 36.71 | 8.55 | 4.26 |
| CEPS(Rs) | 28.59 | 29.11 | 41.05 | 11.66 | 6.81 |
| DPS(Rs) | 1.80 | 1.50 | 1.50 | 1.00 | - |
| Book NAV/Share(Rs) | 133.00 | 104.36 | 83.21 | 47.42 | 38.93 |
| Tax Rate(%) | 25.22 | 25.15 | 25.76 | 24.67 | 29.43 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.50 | 25.31 | 32.47 | 16.98 | 13.72 |
| EBIT Margin(%) | 20.04 | 24.15 | 31.24 | 16.05 | 12.14 |
| Pre Tax Margin(%) | 19.53 | 23.45 | 30.02 | 13.10 | 8.54 |
| PAT Margin (%) | 14.60 | 17.55 | 22.29 | 9.87 | 6.03 |
| Cash Profit Margin (%) | 16.41 | 19.47 | 23.85 | 12.13 | 8.66 |
| Performance Ratios | |||||
| ROA(%) | 16.37 | 19.16 | 33.50 | 10.89 | 6.32 |
| ROE(%) | 21.44 | 27.98 | 58.74 | 21.97 | 13.84 |
| ROCE(%) | 27.40 | 33.74 | 60.80 | 21.45 | 14.88 |
| Asset Turnover(x) | 1.12 | 1.09 | 1.50 | 1.10 | 1.05 |
| Sales/Fixed Asset(x) | 2.84 | 2.62 | 3.29 | 2.04 | 2.21 |
| Working Capital/Sales(x) | 3.00 | 2.64 | 3.60 | 3.34 | 3.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.35 | 0.38 | 0.30 | 0.49 | 0.45 |
| Receivable days | 47.36 | 50.91 | 38.45 | 48.49 | 47.85 |
| Inventory Days | 89.79 | 99.29 | 77.64 | 112.82 | 108.86 |
| Payable days | 25.39 | 24.97 | 23.89 | 29.07 | 18.04 |
| Valuation Parameters | |||||
| PER(x) | 6.55 | 9.99 | 5.05 | 4.99 | 10.56 |
| PCE(x) | 6.89 | 9.00 | 4.52 | 3.66 | 6.61 |
| Price/Book(x) | 1.48 | 2.51 | 2.23 | 0.90 | 1.16 |
| Yield(%) | 0.91 | 0.57 | 0.81 | 2.34 | - |
| EV/Net Sales(x) | 1.14 | 1.76 | 1.14 | 0.72 | 0.91 |
| EV/Core EBITDA(x) | 5.24 | 6.75 | 3.45 | 4.11 | 6.13 |
| EV/EBIT(x) | 5.71 | 7.28 | 3.65 | 4.49 | 7.46 |
| EV/CE(x) | 1.16 | 1.89 | 1.46 | 0.73 | 0.89 |
| M Cap / Sales | 1.13 | 1.75 | 1.08 | 0.44 | 0.57 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.55 | -13.14 | 79.05 | 22.39 | 13.13 |
| Core EBITDA Growth(%) | -2.32 | -31.43 | 237.04 | 45.31 | 29.16 |
| EBIT Growth(%) | -3.28 | -32.84 | 248.46 | 61.82 | 21.34 |
| PAT Growth(%) | -3.04 | -31.61 | 304.54 | 100.33 | 46.64 |
| EPS Growth(%) | 14.57 | -28.52 | 329.32 | 100.60 | 29.71 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.09 | 0.21 | 0.61 | 0.74 |
| Current Ratio(x) | 2.74 | 2.95 | 2.33 | 2.06 | 2.14 |
| Quick Ratio(x) | 1.43 | 1.51 | 1.24 | 0.81 | 0.90 |
| Interest Cover(x) | 38.69 | 34.22 | 25.72 | 5.43 | 3.37 |
| Total Debt/Mcap(x) | 0.04 | 0.03 | 0.09 | 0.68 | 0.64 |
Compare Financial Ratios of peers of TITAN BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TITAN BIOTECH | ₹407.2 Cr | 6.7% | -12.2% | 138.9% | Stock Analytics | |
| PIDILITE INDUSTRIES | ₹150,106.0 Cr | 4% | 9.7% | 25.7% | Stock Analytics | |
| SOLAR INDUSTRIES INDIA | ₹79,629.4 Cr | 7.9% | 35.1% | 139.9% | Stock Analytics | |
| SRF | ₹77,525.5 Cr | 6.1% | 8.2% | 8.6% | Stock Analytics | |
| GUJARAT FLUOROCHEMICALS | ₹40,277.6 Cr | -0.8% | -13% | 0.9% | Stock Analytics | |
| DEEPAK NITRITE | ₹32,593.8 Cr | 1.2% | -7.2% | 20.3% | Stock Analytics | |
TITAN BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TITAN BIOTECH | 6.7% |
-12.2% |
138.9% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
